The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Tardive Dyskinesia (TD) Treatment-Global Market Insights and Sales Trends 2025
Synopsis
Tardive dyskinesia (TD) treatment includes medical interventions and therapies used to manage the involuntary and repetitive movements associated with tardive dyskinesia, a side effect of certain medications.
The global Tardive Dyskinesia (TD) Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Tardive Dyskinesia (TD) Treatment in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Tardive Dyskinesia (TD) Treatment market. Valbenazine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Amantadine segment is estimated at % CAGR for the next seven-year period.
The market for tardive dyskinesia treatment is driven by the demand for effective and safe treatments to alleviate the symptoms of TD and improve patients' quality of life. The market's growth is also influenced by ongoing research in neurology and the development of targeted therapies for movement disorders.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Tardive Dyskinesia (TD) Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Tardive Dyskinesia (TD) Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Tardive Dyskinesia (TD) Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Tardive Dyskinesia (TD) Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Tardive Dyskinesia (TD) Treatment covered in this report include Teva Pharma, Biogen, Johnson & Johnson, GlaxoSmithKline, Neurocrine Biosciences, Pfizer, Novartis, Sanofi and AstraZeneca, etc.
The global Tardive Dyskinesia (TD) Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Teva Pharma
Biogen
Johnson & Johnson
GlaxoSmithKline
Neurocrine Biosciences
Pfizer
Novartis
Sanofi
AstraZeneca
Bayer AG
Global Tardive Dyskinesia (TD) Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Tardive Dyskinesia (TD) Treatment market, Segment by Type:
Valbenazine
Amantadine
Tetrabenazine
Clonazepam
Global Tardive Dyskinesia (TD) Treatment market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Tardive Dyskinesia (TD) Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Tardive dyskinesia (TD) treatment includes medical interventions and therapies used to manage the involuntary and repetitive movements associated with tardive dyskinesia, a side effect of certain medications.
The global Tardive Dyskinesia (TD) Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Tardive Dyskinesia (TD) Treatment in various end use industries. The expanding demands from the Hospitals, Clinics and Others,, are propelling Tardive Dyskinesia (TD) Treatment market. Valbenazine, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Amantadine segment is estimated at % CAGR for the next seven-year period.
The market for tardive dyskinesia treatment is driven by the demand for effective and safe treatments to alleviate the symptoms of TD and improve patients' quality of life. The market's growth is also influenced by ongoing research in neurology and the development of targeted therapies for movement disorders.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Tardive Dyskinesia (TD) Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Tardive Dyskinesia (TD) Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Tardive Dyskinesia (TD) Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Tardive Dyskinesia (TD) Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Tardive Dyskinesia (TD) Treatment covered in this report include Teva Pharma, Biogen, Johnson & Johnson, GlaxoSmithKline, Neurocrine Biosciences, Pfizer, Novartis, Sanofi and AstraZeneca, etc.
The global Tardive Dyskinesia (TD) Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Teva Pharma
Biogen
Johnson & Johnson
GlaxoSmithKline
Neurocrine Biosciences
Pfizer
Novartis
Sanofi
AstraZeneca
Bayer AG
Global Tardive Dyskinesia (TD) Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Tardive Dyskinesia (TD) Treatment market, Segment by Type:
Valbenazine
Amantadine
Tetrabenazine
Clonazepam
Global Tardive Dyskinesia (TD) Treatment market, by Application
Hospitals
Clinics
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Tardive Dyskinesia (TD) Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Tardive Dyskinesia (TD) Treatment
1.1 Tardive Dyskinesia (TD) Treatment Market Overview
1.1.1 Tardive Dyskinesia (TD) Treatment Product Scope
1.1.2 Tardive Dyskinesia (TD) Treatment Market Status and Outlook
1.2 Global Tardive Dyskinesia (TD) Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Tardive Dyskinesia (TD) Treatment Market Size by Region (2018-2029)
1.4 Global Tardive Dyskinesia (TD) Treatment Historic Market Size by Region (2018-2023)
1.5 Global Tardive Dyskinesia (TD) Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Tardive Dyskinesia (TD) Treatment Market Size (2018-2029)
1.6.1 North America Tardive Dyskinesia (TD) Treatment Market Size (2018-2029)
1.6.2 Europe Tardive Dyskinesia (TD) Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Tardive Dyskinesia (TD) Treatment Market Size (2018-2029)
1.6.4 Latin America Tardive Dyskinesia (TD) Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Tardive Dyskinesia (TD) Treatment Market Size (2018-2029)
2 Tardive Dyskinesia (TD) Treatment Market by Type
2.1 Introduction
2.1.1 Valbenazine
2.1.2 Amantadine
2.1.3 Tetrabenazine
2.1.4 Clonazepam
2.2 Global Tardive Dyskinesia (TD) Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Tardive Dyskinesia (TD) Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Tardive Dyskinesia (TD) Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Tardive Dyskinesia (TD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Tardive Dyskinesia (TD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Tardive Dyskinesia (TD) Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Tardive Dyskinesia (TD) Treatment Revenue Breakdown by Type (2018-2029)
3 Tardive Dyskinesia (TD) Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Others
3.2 Global Tardive Dyskinesia (TD) Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Tardive Dyskinesia (TD) Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Tardive Dyskinesia (TD) Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Tardive Dyskinesia (TD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Tardive Dyskinesia (TD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Tardive Dyskinesia (TD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Tardive Dyskinesia (TD) Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Tardive Dyskinesia (TD) Treatment Revenue Breakdown by Application (2018-2029)
4 Tardive Dyskinesia (TD) Treatment Competition Analysis by Players
4.1 Global Tardive Dyskinesia (TD) Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Tardive Dyskinesia (TD) Treatment as of 2022)
4.3 Date of Key Players Enter into Tardive Dyskinesia (TD) Treatment Market
4.4 Global Top Players Tardive Dyskinesia (TD) Treatment Headquarters and Area Served
4.5 Key Players Tardive Dyskinesia (TD) Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Tardive Dyskinesia (TD) Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Teva Pharma
5.1.1 Teva Pharma Profile
5.1.2 Teva Pharma Main Business
5.1.3 Teva Pharma Tardive Dyskinesia (TD) Treatment Products, Services and Solutions
5.1.4 Teva Pharma Tardive Dyskinesia (TD) Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 Teva Pharma Recent Developments
5.2 Biogen
5.2.1 Biogen Profile
5.2.2 Biogen Main Business
5.2.3 Biogen Tardive Dyskinesia (TD) Treatment Products, Services and Solutions
5.2.4 Biogen Tardive Dyskinesia (TD) Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Biogen Recent Developments
5.3 Johnson & Johnson
5.3.1 Johnson & Johnson Profile
5.3.2 Johnson & Johnson Main Business
5.3.3 Johnson & Johnson Tardive Dyskinesia (TD) Treatment Products, Services and Solutions
5.3.4 Johnson & Johnson Tardive Dyskinesia (TD) Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 GlaxoSmithKline Recent Developments
5.4 GlaxoSmithKline
5.4.1 GlaxoSmithKline Profile
5.4.2 GlaxoSmithKline Main Business
5.4.3 GlaxoSmithKline Tardive Dyskinesia (TD) Treatment Products, Services and Solutions
5.4.4 GlaxoSmithKline Tardive Dyskinesia (TD) Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 GlaxoSmithKline Recent Developments
5.5 Neurocrine Biosciences
5.5.1 Neurocrine Biosciences Profile
5.5.2 Neurocrine Biosciences Main Business
5.5.3 Neurocrine Biosciences Tardive Dyskinesia (TD) Treatment Products, Services and Solutions
5.5.4 Neurocrine Biosciences Tardive Dyskinesia (TD) Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Neurocrine Biosciences Recent Developments
5.6 Pfizer
5.6.1 Pfizer Profile
5.6.2 Pfizer Main Business
5.6.3 Pfizer Tardive Dyskinesia (TD) Treatment Products, Services and Solutions
5.6.4 Pfizer Tardive Dyskinesia (TD) Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Pfizer Recent Developments
5.7 Novartis
5.7.1 Novartis Profile
5.7.2 Novartis Main Business
5.7.3 Novartis Tardive Dyskinesia (TD) Treatment Products, Services and Solutions
5.7.4 Novartis Tardive Dyskinesia (TD) Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Novartis Recent Developments
5.8 Sanofi
5.8.1 Sanofi Profile
5.8.2 Sanofi Main Business
5.8.3 Sanofi Tardive Dyskinesia (TD) Treatment Products, Services and Solutions
5.8.4 Sanofi Tardive Dyskinesia (TD) Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Sanofi Recent Developments
5.9 AstraZeneca
5.9.1 AstraZeneca Profile
5.9.2 AstraZeneca Main Business
5.9.3 AstraZeneca Tardive Dyskinesia (TD) Treatment Products, Services and Solutions
5.9.4 AstraZeneca Tardive Dyskinesia (TD) Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 AstraZeneca Recent Developments
5.10 Bayer AG
5.10.1 Bayer AG Profile
5.10.2 Bayer AG Main Business
5.10.3 Bayer AG Tardive Dyskinesia (TD) Treatment Products, Services and Solutions
5.10.4 Bayer AG Tardive Dyskinesia (TD) Treatment Revenue (US$ Million) & (2018-2023)
5.10.5 Bayer AG Recent Developments
6 North America
6.1 North America Tardive Dyskinesia (TD) Treatment Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Tardive Dyskinesia (TD) Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Tardive Dyskinesia (TD) Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Tardive Dyskinesia (TD) Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Tardive Dyskinesia (TD) Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Tardive Dyskinesia (TD) Treatment Market Dynamics
11.1 Tardive Dyskinesia (TD) Treatment Industry Trends
11.2 Tardive Dyskinesia (TD) Treatment Market Drivers
11.3 Tardive Dyskinesia (TD) Treatment Market Challenges
11.4 Tardive Dyskinesia (TD) Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
